Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles

Biochimica et Biophysica Acta - Biomembranes

Volumn 1858, Issue 7, 2016, Pages 1436-1442

  Sarabipour, Sarvenaz ^a   Hristova, Kalina ^a  

^a Johns Hopkins University   (United States)

Author keywords

Achondroplasia; Dimer stability; Dimerization; Fibroblast growth factor receptor 3; Receptor tyrosine kinases; skeletal disorders

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; BACTERIAL PROTEIN; FGFR3 PROTEIN, HUMAN; LIGAND; PHOTOPROTEIN; PROTEIN BINDING; RED FLUORESCENT PROTEIN; YELLOW FLUORESCENT PROTEIN, BACTERIA;

ACHONDROPLASIA; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CHO CELL LINE; CONTROLLED STUDY; CYTOPLASM; DIMERIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GERMLINE MUTATION; LIGAND BINDING; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; AMINO ACID SEQUENCE; ANIMAL; CELL MEMBRANE; CHEMISTRY; CRICETULUS; DRUG EFFECTS; EXOSOME; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; OSMOSIS; PROTEIN MULTIMERIZATION; REPORTER GENE; SIGNAL TRANSDUCTION;

ACHONDROPLASIA; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BACTERIAL PROTEINS; CELL MEMBRANE; CHO CELLS; CRICETULUS; EXTRACELLULAR VESICLES; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; LIGANDS; LUMINESCENT PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; OSMOSIS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION;

EID: 84964330961     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2016.03.027     Document Type: Article

References (59)

1. W.A. Horton, J.G. Hall, and J.T. Hecht Achondroplasia Lancet 370 2007 162 172
2. S. Foldynova-Trantirkova, W.R. Wilcox, and P. Krejci Sixteen Years and Counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias Hum. Mutat. 33 2012 29 41
3. R. Shiang, L.M. Thompson, Y.-Z. Zhu, D.M. Church, T.J. Fielder, M. Bocian, S.T. Winokur, and J.J. Wasmuth Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia Cell 78 1994 335 342
4. C. Deng, A. Wynshaw-Boris, F. Zhou, A. Kuo, and P. Leder Fibroblast growth factor receptor 3 is a negative regulator of bone growth Cell 84 1996 911 921
5. M.M. Cohen Some chondrodysplasias with short limbs: molecular perspectives Am. J. Med. Genet. 112 2002 304 313
6. J.S. Colvin, B.A. Bohne, G.W. Harding, D.G. Mcewen, and D.M. Ornitz Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3 Nat. Genet. 12 1996 390 397
7. Z. Vajo, C.A. Francomano, and D.J. Wilkin The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans Endocr. Rev. 21 2000 23 39
8. R. Goetz, and M. Mohammadi Exploring mechanisms of FGF signalling through the lens of structural biology Nat. Rev. Mol. Cell Biol. 14 2013 166 180
9. M. Mohammadi, S.K. Olsen, and O.A. Ibrahimi Structural basis for fibroblast growth factor receptor activation Cytokine Growth Factor Rev. 16 2005 107 137
10. V.P. Eswarakumar, I. Lax, and J. Schlessinger Cellular signaling by fibroblast growth factor receptors Cytokine Growth Factor Rev. 16 2005 139 149
11. Y. Li, K. Mangasarian, A. Mansukhani, and C. Basilico Activation of FGF receptors by mutations in the transmembrane domain Oncogene 14 1997 1397 1406
12. L. He, W.A. Horton, and K. Hristova The physical basis behind achondroplasia, the most common form of human dwarfism J. Biol. Chem. 285 2010 30103 30114
13. M.C. Naski, Q. Wang, J.S. Xu, and D.M. Ornitz Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia Nat. Genet. 13 1996 233 237
14. P. Krejci, L. Salazar, T.A. Kashiwada, K. Chlebova, A. Salasova, L.M. Thompson, V. Bryja, A. Kozubik, and W.R. Wilcox Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage PLoS One 3 2008
15. M.M. Cohen Achondroplasia, hypochondroplasia and thanatophoric dysplasia: clinically related skeletal dysplasias that are also related at the molecular level Int. J. Oral Maxillofac. Surg. 27 1998 451 455
16. A.O.M. Wilkie Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations Cytokine Growth Factor Rev. 16 2005 187 203
17. M.K. Webster, and D.J. Donoghue FGFR activation in skeletal disorders: too much of a good thing Trends Genet. 13 1997 178 182
18. P. Krejci, J. Prochazkova, J. Smutny, K. Chlebova, P. Lin, A. Aklian, V. Bryja, A. Kozubik, and W.R. Wilcox FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence Bone 47 2010 102 110
19. M. Buchtova, V. Oralova, A. Aklian, J. Masek, I. Vesela, Z.F. Ouyang, T. Obadalova, Z. Konecna, T. Spoustova, T. Pospisilova, P. Matula, M. Varecha, L. Balek, I. Gudernova, I. Jelinkova, I. Duran, I. Cervenkova, S. Murakami, A. Kozubik, P. Dvorak, V. Bryja, and P. Krejci Fibroblast growth factor and canonical WNT/beta-catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage Biochim. Biophys. Acta Mol. basis Dis. 1852 2015 839 850
20. M.C. Naski, J.S. Colvin, J.D. Coffin, and D.M. Ornitz Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3 Development 125 1998 4977 4988
21. C.G.M. L'Horte, and M.A. Knowles Cell responses to FGFR3 signaling: growth, differentiation and apoptosis Exp. Cell Res. 304 2005 417 431
22. S. Sarabipour, and K. Hristova Mechanism of FGF receptor dimerization and activation Nat. Commun. 7 2016 10262
23. M.K. Webster, and D.J. Donoghue Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia EMBO J. 15 1996 520 527
24. M. You, E. Li, and K. Hristova The achondroplasia mutation does not alter the dimerization energetics of FGFR3 transmembrane domain Biochemistry 45 2006 5551 5556
25. J. Placone, and K. Hristova Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET PLoS One 7 2012 e46678
26. S. Sarabipour, R.B. Chan, B. Zhou, G. Di Paolo, and K. Hristova Analytical characterization of plasma membrane-derived vesicles produced via osmotic and chemical vesiculation Biochim. Biophys. Acta 1848 2015 1591 1598
27. S. Sarabipour, N. Del Piccolo, and K. Hristova Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging Forster resonance energy transfer Acc. Chem. Res. 48 2015 2262 2269
28. P. Krejci, D. Krakow, P.B. Mekikian, and W.R. Wilcox Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in human fetal growth plate cartilage Pediatr. Res. 61 2007 267 272
29. G.A. Meyers, S.J. Orlow, I.R. Munro, K.A. Przylepa, and E.W. Jabs Fibroblast-growth-factor-receptor-3 (Fgfr3) transmembrane mutation in Crouzon-syndrome with acanthosis nigricans Nat. Genet. 11 1995 462 464
30. L.R. Chen, L. Novicky, M. Merzlyakov, T. Hristov, and K. Hristova Measuring the energetics of membrane protein dimerization in mammalian membranes J. Am. Chem. Soc. 132 2010 3628 3635
31. L. Chen, J. Placone, L. Novicky, and K. Hristova The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization Sci. Signal. 3 2010 ra86
32. N. Del Piccolo, J. Placone, L. He, S.C. Agudelo, and K. Hristova Production of plasma membrane vesicles with chloride salts and their utility as a cell membrane mimetic for biophysical characterization of membrane protein interactions Anal. Chem. 84 2012 8650 8655
33. S. Sarabipour, C. King, and K. Hristova Un-induced high-yield bacterial expression of fluorescent proteins Anal. Biochem. 449 2014 155 157
34. E. Li, J. Placone, M. Merzlyakov, and K. Hristova Quantitative measurements of protein interactions in a crowded cellular environment Anal. Chem. 80 2008 5976 5985
35. T.H. Evers, E.M.W.M. van Dongen, A.C. Faesen, E.W. Meijer, and M. Merkx Quantitative understanding of the energy transfer between fluorescent proteins connected via flexible peptide linkers Biochemistry 45 2006 13183 13192
36. S. Sarabipour, and K. Hristova FGFR3 unliganded dimer stabilization by the juxtamembrane domain J. Mol. Biol. 427 2015 1705 1714
37. S. Sarabipour, and K. Hristova FGFR3 transmembrane domain interactions persist in the presence of its extracellular domain Biophys. J. 105 2013 165 171
38. F. Chen, C. Degnin, M.B. Laederich, A.W. Horton, and K. Hristova The A391E mutation enhances FGFR3 activation in the absence of ligand Biochim. Biophys. Acta Biomembr. 1808 2011 2045 2050
39. F.H. Chen, and K. Hristova The physical basis of FGFR3 response to fgf1 and fgf2 Biochemistry 50 2011 8576 8582
40. R.E. Scott Plasma membrane vesiculation: a new technique for isolation of plasma membrane Science 194 1976 743 745
41. R.E. Scott, and P.B. Maercklein Plasma-Membrane vesiculation in 3 T3-Cells and Sv 3 T3 cells.2. factors Affecting the process of vesiculation J. Cell Sci. 35 1979 245 252
42. R.E. Scott, R.G. Perkins, M.A. Zschunke, B.J. Hoerl, and P.B. Maercklein Plasma-membrane vesiculation in 3T3-Cells and Sv3T3-cells.1. Morphological and biochemical characterization J. Cell Sci. 35 1979 229 243
43. J. Adler, A.I. Shevchuk, P. Novak, Y.E. Korchev, and I. Parmryd Plasma membrane topography and interpretation of single-particle tracks Nat. Methods 7 2010 170 171
44. I. Parmryd, and B. Onfelt Consequences of membrane topography FEBS. J. 280 2013 2775 2784
45. C. King, M. Stoneman, V. Raicu, and K. Hristova Fully quantified spectral imaging reveals in vivo membrane protein interactions Integr. Biol. (Camb.) 8 2016 216 229
46. D. Holowka, and B. Baird Structural studies on the membrane-bound immunoglobulin E-receptor complex.1. Characterization of large plasma-membrane vesicles from rat basophilic leukemia-cells and insertion of amphipathic fluorescent-probes Biochemistry 22 1983 3466 3474
47. S.L. Veatch, P. Cicuta, P. Sengupta, A. Honerkamp-Smith, D. Holowka, and B. Baird Critical fluctuations in plasma membrane vesicles ACS Chem. Biol. 3 2008 287 293
48. T. Baumgart, A.T. Hammond, P. Sengupta, S.T. Hess, D.A. Holowka, B.A. Baird, and W.W. Webb Large-scale fluid/fluid phase separation of proteins and lipids in giant plasma membrane vesicles Proc. Natl. Acad. Sci. U. S. A. 104 2007 3165 3170
49. J. Placone, L. He, N. Del Piccolo, and K. Hristova Strong dimerization of wild-type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu mutant in mammalian plasma membranes Biochim. Biophys. Acta 1838 2014 2326 2330
50. B. Metz, G.F.A. Kersten, P. Hoogerhout, H.F. Brugghe, H.A.M. Timmermans, A. de Jong, H. Meiring, J. ten Hove, W.E. Hennink, D.J.A. Crommelin, and W. Jiskoot Identification of formaldehyde-induced modifications in proteins - reactions with model peptides J. Biol. Chem. 279 2004 6235 6243
51. S. Sarabipour, and K. Hristova Glycophorin A transmembrane domain dimerization in plasma membrane vesicles derived from CHO, HEK 293T, and A431 cells Biochim. Biophys. Acta 1828 2013 1829 1833
52. L. He, W.C. Wimley, and K. Hristova FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism J. Biol. Chem. 286 2011 13272 13281
53. C.C. Lin, F.A. Melo, R. Ghosh, K.M. Suen, L.J. Stagg, J. Kirkpatrick, S.T. Arold, Z. Ahmed, and J.E. Ladbury Inhibition of basal FGF receptor signaling by dimeric Grb2 Cell 149 2012 1514 1524
54. A.N. Seo, Y. Jin, H.J. Lee, P.L. Sun, H. Kim, S. Jheon, K. Kim, C.T. Lee, and J.H. Chung FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer Virchows Arch. 465 2014 547 558
55. N. Turner, A. Pearson, R. Sharpe, M. Lambros, F. Geyer, M.A. Lopez-Garcia, R. Natrajan, C. Marchio, E. Iorns, A. Mackay, C. Gillett, A. Grigoriadis, A. Tutt, J.S. Reis, and A. Ashworth FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer Cancer Res. 70 2010 2085 2094
56. L. Xie, X.Y. Su, L. Zhang, X.L. Yin, L.L. Tang, X.H. Zhang, Y.P. Xu, Z.R. Gao, K.J. Liu, M.H. Zhou, B.R. Gao, D.P. Shen, L.H. Zhang, J.F. Ji, P.R. Gavine, J.C. Zhang, E. Kilgour, X.L. Zhang, and Q.S. Ji FGFR2 Gene amplification in Gastric cancer Predicts Sensitivity to the Selective FGFR inhibitor AZD4547 Clin. Cancer Res. 19 2013 2572 2583
57. M. Chesi, E. Nardini, R.S.C. Lim, K.D. Smith, W.M. Kuehl, and P.L. Bergsagel The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts Blood 92 1998 3025 3034
58. M. Chesi, E. Nardini, L.A. Brents, E. Schrock, T. Ried, W.M. Kuehl, and P.L. Bergsagel Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 Nat. Genet. 16 1997 260 264
59. M.L. Cunningham, M.L. Seto, C. Ratisoontorn, C.L. Heike, and A.V. Hing Syndromic craniosynostosis: from history to hydrogen bonds Orthod. Craniofacial Res. 10 2007 67 81